Company AEterna Zentaris Inc. Nasdaq
Equities
CA0079753038
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Business Summary
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 7 | 100.0 % | 6 | 100.0 % | -17.32% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Switzerland
96.0
%
| 7 | 95.7 % | 6 | 96.0 % | -17.04% |
Ireland
2.7
%
| 0 | 1.5 % | 0 | 2.7 % | +54.25% |
Other
1.1
%
| 0 | 0.1 % | 0 | 1.1 % | +1,558.79% |
Denmark
0.2
%
| 0 | 2.8 % | 0 | 0.2 % | -92.87% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Gilles Gagnon
CEO | Chief Executive Officer | 70 | 98-12-31 |
Director of Finance/CFO | - | 22-01-23 | |
Patricia Zahn
ADM | Chief Administrative Officer | - | 15-09-30 |
Nicola Ammer
CTO | Chief Tech/Sci/R&D Officer | - | 14-01-31 |
Michael Teifel
CTO | Chief Tech/Sci/R&D Officer | - | 03-12-31 |
Matthias Gerlach
PRN | Corporate Officer/Principal | - | 00-12-31 |
Eckhard Guenther
PRN | Corporate Officer/Principal | - | 05-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gilles Gagnon
CEO | Chief Executive Officer | 70 | 19-12-31 |
Peter Edwards
BRD | Director/Board Member | 62 | 20-05-14 |
Dennis Turpin
BRD | Director/Board Member | - | 21-05-04 |
Carolyn Egbert
CHM | Chairman | - | 12-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,061,688 | 3,012,875 ( 98.41 %) | 0 | 98.41 % |
Company contact information
![address AEterna Zentaris Inc.](https://cdn.zonebourse.com/static/address/11705947.png)
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.44B | |
+42.78% | 40.03B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.29B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- AEZS Stock
- Stock
- Company AEterna Zentaris Inc.